Amy Barnett, MD
Internal Medicine · Knoxville, TNNPI 1285848408
Payments from drug & device makers
Across 126 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$294
- Amgen$199
- Pfizer$191
- GSK$152
- Boehringer Ingelheim$134
- Lilly USA, LLC$131
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,116100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $294 |
| Amgen | 14 | $199 |
| Pfizer | 11 | $191 |
| GSK | 10 | $152 |
| Boehringer Ingelheim | 6 | $134 |
| Lilly USA, LLC | 9 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Bayer | 6 | $89 |
| AstraZeneca | 5 | $82 |
| Astellas Pharma US Inc | 4 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Johnson & Johnson(2 entities) | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Philips North America LLC | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Abbott | 2 | $36 |
| Exact Sciences | 2 | $28 |
| AbbVie | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Electromed, Inc. | 2 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,116 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 95 | $135,982 |
| MounjaroTirzepatide | 79 | $122,792 |
| EliquisApixaban | 121 | $121,861 |
| JardianceEmpagliflozin | 68 | $83,327 |
| KerendiaFinerenone | 49 | $51,869 |
| MyrbetriqMirabegron | 45 | $40,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $40,485 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $38,172 |
| OzempicSemaglutide | 16 | $32,758 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 84 | $26,778 |
| XareltoRivaroxaban | 21 | $19,284 |
| FarxigaDapagliflozin Propanediol | 19 | $17,876 |
| JanuviaSitagliptin Phosphate | 12 | $15,153 |
| Spiriva RespimatTiotropium Bromide | 18 | $14,741 |
| Repatha SureclickEvolocumab | 16 | $12,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $131 | $258,774174 claims |
| PfizerEliquis, Abrysvo | $191 | $148,639205 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $134 | $106,11999 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $152 | $55,87484 claims |
| BayerKerendia | $89 | $51,86949 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $40,96245 claims |
| Novo NordiskOzempic | $294 | $32,75816 claims |
| Johnson & JohnsonXarelto | $62 | $19,28421 claims |
| AstraZenecaFarxiga | $82 | $17,87619 claims |
| AbbVieLinzess, Synthroid | $24 | $10,20744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Knoxville
- Amanda Moore MillerKnoxville$2.3M
- George NewmanKnoxville$682K
- Dennis DeruelleKnoxville$263K
- Lewis HagoodKnoxville$143K
- Johnny AltawilKnoxville$23K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.